

OPEN ACCESS

APPROVED BY

Frontiers Editorial Office, Frontiers Media SA, Switzerland

*CORRESPONDENCE

Frontiers Production Office

☐ production.office@frontiersin.org

SPECIALTY SECTION

This article was submitted to Nuclear Medicine, a section of the journal Frontiers in Medicine

RECEIVED 10 March 2023 ACCEPTED 10 March 2023 PUBLISHED 22 March 2023

CITATION

Frontiers Production Office (2023) Erratum: Overview of the RGD-based PET agents use in patients with cardiovascular diseases: A systematic review. *Front. Med.* 10:1183711. doi: 10.3389/fmed.2023.1183711

COPYRIGHT

© 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Erratum: Overview of the RGD-based PET agents use in patients with cardiovascular diseases: A systematic review

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

KEYWORDS

 $\alpha\nu\beta_3$ integrin, RGD, angiogenesis, positron emission tomography, cardiovascular diseases, myocardial infarction, atherosclerosis

An Erratum on

Overview of the RGD-based PET agents use in patients with cardiovascular diseases: A systematic review

by Dietz, M., Kamani, C. H., Dunet, V., Fournier, S., Rubimbura, V., Testart Dardel, N., Schaefer, A., Jreige, M., Boughdad, S., Nicod Lalonde, M., Schaefer, N., Mewton, N., Prior, J. O., and Treglia, G. (2022). Front. Med. 9:887508. doi: 10.3389/fmed.2022.887508

An omission to the funding section of the original article was made in error. The following sentence has been added: "Open access funding was provided by the University of Lausanne."

The original article has been updated.